LYTIR

Company · SYRE

Spyre Therapeutics, Inc.

Nasdaq's symbol directory lists SYRE on Nasdaq as “Spyre Therapeutics, Inc. - Common Stock”.

In the 12 months to Nov 8, 2026: insiders sold on 18 occasions ($422.6M); 3 planned-sale notices; 5 filings by holders of 5% or more; 2 company reports (Form 8-K, since May 26, 2026).

All insider filings at the SEC · Appeared in No. 15

Insider purchases and sales, by month (last 12 months)Insider purchases: $0 in total; Insider sales: $422.6M in total.Jun: Insider sales $403.0MJul: Insider sales $2.7MAug: Insider sales $4.6MSep: Insider sales $7.6MOct: Insider sales $4.7MDecJanFebMarAprMayJunJulAugSepOctNov
Insider purchases above the line: $0Insider sales below: $422.6M
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Fairmount Funds Management LLC sold on 1 day latest Jun 23, 2026 sold $399.7M
  2. Burrows Scott L, Chief Financial Officer sold on 7 days 6 of them under a 10b5-1 plan latest Oct 1, 2026 sold $7.2M
  3. Turtle Cameron, Chief Executive Officer sold on 4 days all under a 10b5-1 plan latest Oct 1, 2026 sold $5.4M
  4. Heidy King-Jones, Chief Legal Officer and Corporate Secretary sold on 3 days all under a 10b5-1 plan latest Oct 1, 2026 sold $5.1M
  5. Albers Jeffrey W. sold on 1 day all under a 10b5-1 plan latest Aug 7, 2026 sold $2.4M
  6. Michael T. Henderson sold on 1 day all under a 10b5-1 plan latest Jun 22, 2026 sold $2.0M
  7. Sloan Sheldon, Chief Medical Officer sold on 1 day all under a 10b5-1 plan latest Jul 1, 2026 sold $731K
Every trade (18)
  1. SELLHeidy King-Jones, Chief Legal Officer and Corporate Secretary sold Oct 1, 2026 28,933 shares 5 legs combined 10b5-1 plan (scheduled) filing $2.6M
  2. SELLTurtle Cameron, Chief Executive Officer sold Oct 1, 2026 15,000 shares 6 legs combined 10b5-1 plan (scheduled) filing $1.4M
  3. SELLBurrows Scott L, Chief Financial Officer sold Oct 1, 2026 7,500 shares 5 legs combined 10b5-1 plan (scheduled) filing $689K
  4. SELLBurrows Scott L, Chief Financial Officer sold Sep 30, 2026 17,500 shares 10b5-1 plan (scheduled) filing $1.6M
  5. SELLBurrows Scott L, Chief Financial Officer sold Sep 2, 2026 18,232 shares 10b5-1 plan (scheduled) filing $1.6M
  6. SELLHeidy King-Jones, See Remarks sold Sep 2, 2026 400 shares 10b5-1 plan (scheduled) filing $36K
  7. SELLHeidy King-Jones, See Remarks sold Sep 1, 2026 27,999 shares 4 legs combined 10b5-1 plan (scheduled) filing $2.4M
  8. SELLTurtle Cameron, Chief Executive Officer sold Sep 1, 2026 15,000 shares 4 legs combined 10b5-1 plan (scheduled) filing $1.3M
  9. SELLBurrows Scott L, Chief Financial Officer sold Sep 1, 2026 7,500 shares 4 legs combined 10b5-1 plan (scheduled) filing $655K
  10. SELLAlbers Jeffrey W. sold Aug 7, 2026 23,000 shares 3 legs combined 10b5-1 plan (scheduled) filing $2.4M
  11. SELLTurtle Cameron, Chief Executive Officer sold Aug 3, 2026 15,000 shares 5 legs combined 10b5-1 plan (scheduled) filing $1.4M
  12. SELLBurrows Scott L, Chief Financial Officer sold Aug 3, 2026 7,500 shares 3 legs combined 10b5-1 plan (scheduled) filing $717K
  13. SELLTurtle Cameron, Chief Executive Officer sold Jul 1, 2026 15,000 shares 3 legs combined 10b5-1 plan (scheduled) filing $1.3M
  14. SELLSloan Sheldon, Chief Medical Officer sold Jul 1, 2026 8,334 shares 2 legs combined 10b5-1 plan (scheduled) filing $731K
  15. SELLBurrows Scott L, Chief Financial Officer sold Jul 1, 2026 7,500 shares 2 legs combined 10b5-1 plan (scheduled) filing $658K
  16. SELLBurrows Scott L, Chief Financial Officer sold Jun 25, 2026 15,000 shares 2 legs combined filing $1.3M
  17. SELLFairmount Funds Management LLC sold Jun 23, 2026 4,684,781 shares filing $399.7M
  18. SELLMichael T. Henderson sold Jun 22, 2026 20,000 shares 10b5-1 plan (scheduled) filing $2.0M

Planned sales · SEC Form 144

Notice given

A Form 144 is filed before an insider sells restricted stock. It states an intent; the sale, if it happens, appears later on a Form 4. Every recent notice

  1. CAMERON TURTLE filed Oct 1, 2026 Director 45,000 shares planned sale date 10/01/2026 filing $4.0M
  2. HEIDY KING-JONES filed Oct 1, 2026 Officer 29,335 shares planned sale date 10/01/2026 filing $2.6M
  3. SCOTT BURROWS filed Sep 30, 2026 Officer 17,500 shares planned sale date 09/30/2026 filing $1.6M

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. Fairmount Funds Management LLC filed Oct 9, 2026 Schedule 13D/A may seek influence 10,185,961 shares filing 9.99%
  2. Paradigm BioCapital Advisors LP filed Oct 1, 2026 Schedule 13G passive filing 5.1%
  3. Perceptive Advisors LLC filed Aug 14, 2026 Schedule 13G/A passive filing 4.9%
  4. RTW Investments, LP filed Aug 14, 2026 Schedule 13G/A passive filing 4.8%
  5. Fairmount Funds Management LLC filed Jun 23, 2026 Schedule 13D/A may seek influence 8,835,440 shares filing 9.15%

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Results of operations and financial condition filing Nov 3, 2026
  2. Entry into a material definitive agreement filing Oct 7, 2026

Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.